Mitchell C Benson
Overview
Explore the profile of Mitchell C Benson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
3746
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papachristodoulou A, Heidegger I, Virk R, Di Bernardo M, Kim J, Laplaca C, et al.
Eur Urol
. 2023 Sep;
85(4):361-372.
PMID: 37659962
Background: The antidiabetic drug metformin has known anticancer effects related to its antioxidant activity; however, its clinical benefit for prostate cancer (PCa) has thus far been inconclusive. Here, we investigate...
2.
Whalen M, Hackert V, Rothberg M, McKiernan J, Benson M, Badani K
Urol Pract
. 2023 Aug;
3(5):379-386.
PMID: 37592572
Introduction: We evaluate the Genomic Prostate Score in a prospective clinical setting and determine the cutoff point for likelihood of favorable pathology, below which definitive treatment should be advised. Methods:...
3.
Danzig M, Berg A, Ghandour R, Lascano D, Whalen M, Benson M, et al.
Urol Pract
. 2023 Aug;
3(1):55-61.
PMID: 37592508
Introduction: Partial cystectomy use has historically been limited by stringent selection criteria. We compared outcomes following partial cystectomy at our institution with those in other contemporary series. Also, we specifically...
4.
Whalen M, RiChard J, Ghandour R, Lipsky M, Piecuch M, Benson M, et al.
Urol Pract
. 2023 Aug;
2(2):90-95.
PMID: 37537804
Introduction: We examined the practice patterns of intraoperative ureteral frozen section during radical cystectomy and the impact of ureteral margin positivity on operative characteristics and oncologic outcomes. Methods: The records...
5.
6.
Pak J, Haas C, Anderson C, DeCastro G, Benson M, McKiernan J
Urol Oncol
. 2021 Apr;
39(11):787.e9-787.e15.
PMID: 33865688
Objectives: Prior studies have shown that pathologic complete response at radical cystectomy, a significant prognostic factor, can be attributed to both neoadjuvant chemotherapy (NAC) and high-quality transurethral resections (TURBT) prior...
7.
Wang E, Pak J, Virk R, Anderson C, Healy K, Lee J, et al.
Urology
. 2020 May;
143:194-205.
PMID: 32437773
Bladder paragangliomas are rare tumors, with no prospective studies or guidelines on the management of this disease. We present a case series of 6 patients managed with bladder preservation over...
8.
9.
Lee S, Hu W, Matulay J, Silva M, Owczarek T, Kim K, et al.
Cell
. 2018 Apr;
173(2):515-528.e17.
PMID: 29625057
Bladder cancer is the fifth most prevalent cancer in the U.S., yet is understudied, and few laboratory models exist that reflect the biology of the human disease. Here, we describe...
10.
Giri V, Knudsen K, Kelly W, Abida W, Andriole G, Bangma C, et al.
J Clin Oncol
. 2017 Dec;
36(4):414-424.
PMID: 29236593
Purpose Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driven working framework for comprehensive genetic evaluation of inherited...